Not every harmful change in the BRCA2 gene carries the same danger of breast cancer, a Mayo Clinic-led study published on 17 November 2026 has found. The researchers identified a group of 70 variants that raise a carrier's lifetime risk to an estimated 20% to 25%, well below the 50% to 70% linked to the more common harmful BRCA2 variants.

The study appeared in the journal Nature Communications and was carried out with investigators from the genetic testing company Ambry Genetics, Mayo Clinic said in a release issued the same day.

What the researchers found

BRCA2 is one of the genes examined in hereditary cancer testing. When a test reports a harmful, or pathogenic, variant, the person is generally treated as being at high risk.

The Mayo team looked at variants that only partly disrupt the working of the BRCA2 protein. Scientists call these "hypomorphic" variants. The researchers studied how each of the 70 variants affects the gene's function and combined that with data from a large number of people who had undergone hereditary cancer testing. The release did not give the exact number of people in that dataset.

Their conclusion, reflected in the paper's title, is that these partly functional variants are disease-causing but with "reduced penetrance", meaning fewer carriers go on to develop cancer than is the case with typical harmful variants.

"This shows that not all harmful BRCA2 variants carry the same level of breast cancer risk," Fergus Couch, a breast cancer researcher at Mayo Clinic Comprehensive Cancer Center, said in the release.

What it could mean for carriers

A lifetime risk of 20% to 25% is still elevated. According to Mayo Clinic, people with these variants may continue to qualify for, and benefit from, regular mammograms and breast MRI scans.

Where the finding could matter most is in bigger decisions. More precise risk estimates could inform choices about risk-reducing surgery, the release said. Couch said that women and men who inherit these variants "should benefit from risk management strategies tailored to the level of risk".

The study also looked at treatment. Some tumours linked to these variants may respond to PARP inhibitors, a class of targeted cancer drugs, and testing the tumour may help show whether that treatment suits a particular patient, according to the release. This was presented as a possibility, not an established result.

The limits

Couch said that only "a small subset of breast cancers are likely caused by BRCA2 hypomorphs". The release did not say how often these variants turn up in testing, and it did not describe any change to current clinical guidelines.

What happens next

The team plans to keep identifying and characterising such partly functional variants in both BRCA1 and BRCA2. "Once the hypomorphic variants are all identified, we will be able to better define risk management and therapeutic strategies," Couch said.

PS